CDK6 Antikörper (AA 1-326)
Kurzübersicht für CDK6 Antikörper (AA 1-326) (ABIN5692992)
Target
Alle CDK6 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
- 
    
- 
                                            
Bindungsspezifität
 - AA 1-326
 - 
                                            
Verwendungszweck
 - Anti-Cdk6 Antibody Picoband®
 - 
                                            
Kreuzreaktivität (Details)
 - No cross-reactivity with other proteins.
 - 
                                            
Produktmerkmale
 - Anti-Cdk6 Antibody Picoband® (ABIN5692992). Tested in ELISA, IHC, WB applications. This antibody reacts with Human, Mouse. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.
 - 
                                            
Immunogen
 - E. coli-derived human Cdk6 recombinant protein (Position: M1-A326).
 - 
                                            
Isotyp
 - IgG
 
 - 
                                            
 - 
    
 - 
    
- 
                                            
Applikationshinweise
 - 
                        Western blot, 0.1-0.5 μg/mL
Immunohistochemistry (Paraffin-embedded Section), 0.5-1 μg/mL
ELISA, 0.1-0.5 μg/mL
1. Lena, A. M., Mancini, M., Rivetti di Val Cervo, P. R., Saintigny, G., Mahe, C., Melino, G., Candi, E. MicroRNA-191 triggers keratinocytes senescence by SATB1 and CDK6 downregulation. Biochem. Biophys. Res. Commun. 423: 509-514, 2012. 2. Lien, H.-C., Lin, C.-W., Huang, P.-H., Chang, M.-L., Hsu, S.-M. Expression of cyclin-dependent kinase 6 (cdk6) and frequent loss of CD44 in nasal-nasopharyngeal NK/T-cell lymphomas: comparison with CD56-negative peripheral T-cell lymphomas. Lab. Invest. 80: 893-900, 2000. 3. Malumbres, M., Sotillo, R., Santamaria, D., Galan, J., Cerezo, A., Ortega, S., Dubus, P., Barbacid, M. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118: 493-504, 2004. 4. Veiga-Fernandes, H., Rocha, B. High expression of active CDK6 in the cytoplasm of CD8 memory cells favors rapid division. Nature Immun. 5: 31-37, 2003. - 
                                            
Beschränkungen
 - Nur für Forschungszwecke einsetzbar
 
 - 
                                            
 - 
    
- 
                                            
Format
 - Lyophilized
 - 
                                            
Rekonstitution
 - Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.
 - 
                                            
Konzentration
 - 500 μg/mL
 - 
                                            
Buffer
 - Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg NaN3.
 - 
                                            
Konservierungsmittel
 - Sodium azide
 - 
                                            
Vorsichtsmaßnahmen
 - This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
 - 
                                            
Lagerung
 - 4 °C,-20 °C
 - 
                                            
Informationen zur Lagerung
 - 
                        Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month. 
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles. 
 - 
                                            
 - 
    
- 
                                            : "TALENs-directed knockout of the full-length transcription factor Nrf1α that represses malignant behaviour of human hepatocellular carcinoma (HepG2) cells."    in: Scientific reports, Vol. 6, pp. 23775, (2017)         (PubMed).        
: "Long noncoding RNA NEAT1 promotes laryngeal squamous cell cancer through regulating miR-107/CDK6 pathway." in: Journal of experimental & clinical cancer research : CR, Vol. 35, pp. 22, (2016) (PubMed).
: "Platycodin D induces tumor growth arrest by activating FOXO3a expression in prostate cancer in vitro and in vivo." in: Current cancer drug targets, Vol. 14, Issue 9, pp. 860-71, (2015) (PubMed).
 
 - 
                                            : "TALENs-directed knockout of the full-length transcription factor Nrf1α that represses malignant behaviour of human hepatocellular carcinoma (HepG2) cells."    in: Scientific reports, Vol. 6, pp. 23775, (2017)         (PubMed).        
 - 
    
- CDK6 (Cyclin-Dependent Kinase 6 (CDK6))
 - 
                                            
Andere Bezeichnung
 - CDK6
 - 
                                            
Hintergrund
 - 
                        
Synonyms: Cyclin-dependent kinase 6, Cell division protein kinase 6, Serine/threonine-protein kinase PLSTIRE, CDK6, CDKN6
Tissue Specificity: Expressed ubiquitously. Accumulates in squamous cell carcinomas, proliferating hematopoietic progenitor cells, beta-cells of pancreatic islets of Langerhans, and neuroblastomas. Reduced levels in differentiating cells.
Background: Cell division protein kinase 6, also called Plstire, is an enzyme that in humans is encoded by the CDK6 gene. The protein encoded by this gene is a member of the cyclin-dependent protein kinase (CDK) family. Radiation hybrid analysis and inclusion within a mapped clone place the CDK6 gene at 7q21. Serine/threonine-protein kinase involved in the control of the cell cycle and differentiation and promotes G1/S transition. This gene also involved in initiation and maintenance of cell cycle exit during cell differentiation. It prevents cell proliferation and regulates negatively cell differentiation, but is required for the proliferation of specific cell types. In addition, CDK6 plays a role in promoting the proliferation of beta-cells in pancreatic islets of Langerhans.
 - 
                                            
Molekulargewicht
 - 37 kDa
 - 
                                            
Gen-ID
 - 1021
 - 
                                            
UniProt
 - Q00534
 - 
                                            
Pathways
 - Zellzyklus, Mitotic G1-G1/S Phases
 
Target
 -